Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04321837
Other study ID # AAAS2051
Secondary ID HS# 2018-4772
Status Completed
Phase Phase 2
First received
Last updated
Start date February 5, 2020
Est. completion date March 13, 2023

Study information

Verified date May 2024
Source Columbia University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study will investigate the effect of coral calcium complex supplementation on BMD of osteoporotic individuals either when used alone or in combination with ibandronate. Ibandronate alone will also be tested in comparison to coral calcium supplementation alone or in combination.


Description:

Osteoporosis and resulting fragility fractures are major causes of morbidity and mortality in older individuals. Current estimates indicate that as many as 50% of American women and 20% of men over the age of 50 will be at risk for osteoporotic fractures during their lifetimes, and that these fractures are associated both with higher risk for further fractures and with higher mortality rates. Osteoporosis and subsequent fragility fractures can be prevented if diagnosed and treated appropriately. The first step of treatment guidelines for individuals with reduced bone mineral density (BMD), as identified with dual energy x-ray absorptiometry (DXA) scan, is the implementation of lifestyle measures to reduce bone loss. These include the supplementation of dietary calcium and vitamin D to maintain appropriate calcium intake and reduce resorption of mineralized calcium from bone. Pharmacological treatment can be used for the treatment of osteoporosis in individuals who have reduced BMD (less than -2.5 T-score) and for those who have sustained a fragility fracture. The bisphosphonates are first line agents for the treatment of osteoporosis. Coral-derived calcium is a novel formulation of calcium supplement, which has not yet been rigorously investigated as an efficacious nutrient for the skeleton. Ibandronate is a commonly available bisphosphonate prescribed for the treatment of osteoporosis. Vitamin D is a nutrient required to absorb vitamin D from the diet.


Recruitment information / eligibility

Status Completed
Enrollment 60
Est. completion date March 13, 2023
Est. primary completion date March 13, 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 50 Years to 75 Years
Eligibility Inclusion Criteria: 1. Postmenopausal women, 50-75 years of age (inclusive). Menopause is defined as no menstrual period for 1 year. 2. BMD T-score of lumbar spine (L1-L4), femoral neck, total hip, or non-dominant forearm < -2.5 as determined by DXA. Exclusion Criteria: 1. T-score of lumbar spine, femoral neck, total hip, or non-dominant forearm < -3.5. 2. Use of any supplemental calcium preparations in the past 1 year. 3. Use of ibandronate in the past 3 years. 4. Current use of 1. prednisone or other corticosteroid, 2. antiseizure medications, 3. thiazide diuretics, or 4. estrogen preparation except vaginal cream. 5. Electrolyte abnormalities, as defined by abnormal blood levels of sodium (Na), chlorine (Cl), potassium (K), phosphate (Phos), calcium (Ca), or magnesium (Mg) values on initial screen. 6. Chronic disease, including 1. liver disease (as defined by elevated blood levels of aspartate aminotransferase, alanine aminotransferase, and/or alkaline phosphatase or reduced albumin or total protein on initial screen), 2. stage III renal disease or worse (as defined by epidermal growth factor receptor (eGFR) < 60 cc/min), 3. abnormal thyroid function tests, 4. current parathyroid disease (as defined by hypercalcemia and elevated levels of parathyroid hormone (PTH) - if history of hyperparathyroidism, surgical cure has to be documented more than 5 years ago), 5. diabetes mellitus, 6. any other known metabolic bone disease besides osteoporosis, and/or 7. any inflammatory, anatomic, or malabsorptive GI tract disease. 7. Osteoporotic fracture in the past 6 months, defined as a low-energy fracture such as a fracture after falling from a standing height.

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
Coral Complex 3
Coral-derived calcium supplement fortified with vitamin D3
Drug:
Ibandronate
Bisphosphonate
Dietary Supplement:
Vitamin D3
Oral vitamin D3

Locations

Country Name City State
Armenia Osteoporosis Center of Armenia Yerevan

Sponsors (3)

Lead Sponsor Collaborator
Columbia University Osteoporosis Center of Armenia, University of California, Irvine

Country where clinical trial is conducted

Armenia, 

Outcome

Type Measure Description Time frame Safety issue
Primary Mean change in bone mineral density (BMD) (lumbar spine) Participant bone mineral density of lumbar spine. 48 weeks
Primary Mean change in BMD (femoral neck) Participant bone mineral density of femoral neck. 48 weeks
Primary Mean change in BMD (total hip) Participant bone mineral density of total hip. 48 weeks
Primary Mean change in BMD (forearm) Participant bone mineral density of forearm. 48 weeks
See also
  Status Clinical Trial Phase
Active, not recruiting NCT03931109 - Circulating miRNA in Primary Hyperparathyroidism
Not yet recruiting NCT03232476 - Effect of Mechanical Loading With PTH on Cortical Bone Phase 4
Completed NCT02884401 - Peri-implant Bone Changes in Post-menopausal Osteoporotic Women N/A
Completed NCT00073190 - Patient- and Physician-Based Osteoporosis Education Phase 1
Completed NCT00402441 - Risedronate in the Prevention of Osteoporosis in Postmenopausal Women Phase 4
Completed NCT03710889 - Early Effects of Abaloparatide on Tissue-Based Indices of Bone Formation and Resorption Phase 3
Completed NCT00010712 - Effects of Black Cohosh on Menopausal Hot Flashes Phase 2
Recruiting NCT05058976 - Romosozumab Use to Build Skeletal Integrity Phase 4
Active, not recruiting NCT05405894 - Efficacy of Zoledronic Acid to Prevent Bone Loss Following Denosumab Discontinuation
Recruiting NCT03337971 - Nutritional Supplement and Bone Health in Post-Menopausal Women N/A
Completed NCT03701113 - Milk Protein and Bone Health in Postmenopausal Women N/A
Completed NCT01381588 - The Prevalence of Osteoporotic Vertebral Compression Fractures (OVCF) in Korean Post Menopausal Women N/A
Completed NCT00383422 - Study Comparing Arzoxifene With Raloxifene in Women After Menopause With Osteoporosis Phase 3
Completed NCT00549965 - Satisfaction and Compliance of Risedronate in PMO Phase 4
Completed NCT00035256 - Sequential Use of Teriparatide and Raloxifene HCl in the Treatment of Postmenopausal Women With Osteoporosis Phase 4
Completed NCT01386281 - Julina Post-marketing Surveillance for Climacteric Symptoms in Japan
Completed NCT05266261 - Use of Ibandronate in Diabetic Patients N/A
Recruiting NCT04964388 - Effect of GLP-1 Receptor Agonists on Trabecular Bone Score Phase 2
Active, not recruiting NCT03623633 - Comparative Antiresorptive Efficacy Discontinuation of Denosumab Phase 4
Recruiting NCT05575167 - Single or Repeat Zoledronate Versus Alendronate Following Denosumab (EUROpean Denosumab Effects Consolidation Study)